Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed

MT Newswires Live

2025/10/30

Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.

Two analysts polled by FactSet expected 66.98 yen.

Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.

Analysts polled by FactSet expected 1.197 trillion yen

The company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.

Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.

Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579111892"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579111892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579111892?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579111892","market":"sg","top_or_hot":-1,"title":"Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.</p><p>Two analysts polled by FactSet expected 66.98 yen.</p><p>Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.</p><p>Analysts polled by FactSet expected 1.197 trillion yen</p><p>The company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.</p><p>Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.</p><p>Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-30 17:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.</p><p>Two analysts polled by FactSet expected 66.98 yen.</p><p>Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.</p><p>Analysts polled by FactSet expected 1.197 trillion yen</p><p>The company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.</p><p>Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.</p><p>Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579111892","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579111892","pubTimestamp":1761816763,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  reported fiscal Q2 core earnings Thursday of 128 Japanese yen  per share, down from 134 yen a year earlier.Two analysts polled by FactSet expected 66.98 yen.Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.Analysts polled by FactSet expected 1.197 trillion yenThe company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田制药第二财季核心盈利、营收下降；2025财年前景下调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Takeda Pharmaceutical (TAK) reported fiscal Q2 core earnings Thursday of 128 Japanese yen ($0.83) per share, down from 134 yen a year earlier.Two analysts polled by FactSet expected 66.98 yen.Revenue for the quarter ended Sept. 30 was 1.113 trillion yen, compared with 1.176 trillion yen a year earlier.Analysts polled by FactSet expected 1.197 trillion yenThe company said it now expects fiscal 2025 core earnings of 479 yen per share, from 485 yen previously. Analysts polled by FactSet expect 246.9 yen.Takeda also lowered its fiscal 2025 revenue guidance to 4.5 trillion yen, from 4.53 trillion yen previously. Analysts polled by FactSet expect 4.582 trillion yen.Shares of Takeda Pharmaceutical were down nearly 2% in recent premarket activity Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}